Abstract
e15576 Background: Axitinib (Inlyta) was approved in January 2012 for treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. The experience of patients and pr...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
